Conversely, in hepatocellular carcinoma (HCC), sorafenib activates the extracellular signal-regulated kinase (ERK) signaling pathway, promoting tripartite motif containing 54 (TRIM54)-mediated ubiquitination and proteasomal degradation of FSP1, thereby reducing FSP1 protein abundance and sensitizing tumor cells to ferroptosis [26]. This evidence concerns the gene AIFM2 and neoplasm.